Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 5,100 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 5,100 shares of the business’s stock in a transaction on Friday, June 6th. The stock was sold at an average price of $56.00, for a total value of $285,600.00. Following the completion of the sale, the insider now directly owns 256,580 shares in the company, valued at $14,368,480. This represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Michael Chi also recently made the following trade(s):

• On Tuesday, June 10th, Michael Chi sold 5,600 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.00, for a total value of $319,200.00.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $57.51 on Thursday. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock’s 50-day moving average is $43.92 and its two-hundred day moving average is $37.81. The firm has a market cap of $12.87 billion, a P/E ratio of 130.71 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same period in the prior year, the firm posted $0.05 EPS. The business’s revenue was up 110.7% compared to the same quarter last year. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Blume Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the 1st quarter valued at approximately $30,000. Smartleaf Asset Management LLC boosted its stake in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter worth approximately $38,000. Finally, UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after acquiring an additional 933 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on HIMS shares. Leerink Partners boosted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Saturday, June 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday. Piper Sandler reaffirmed a “neutral” rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.